FDA Panel Recommends High-Dose EPA for CV Event Reduction FDA Panel Recommends High-Dose EPA for CV Event Reduction

Icosapent ethyl (Vascepa, Amarin) was unanimously recommended for approval as an adjunct to statin therapy. However, the exact population for whom the drug should be prescribed was not decided.News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news